Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
Zinforo®: High clinical cure rate and evidence of rapid response in cSSTI
Clinical cure rates: CANVAS 1 and 2
CANVAS 1 and 2 trials: Two Phase III, randomised, double-blind, international, multicentre, comparative efficacy and safety trials comparing Zinforo (600 mg IV q12h ± placebo q12h, adjusted for moderate renal impairment) vs vancomycin + aztreonam (1 g IV q12h)2
Zinforo 600 mg every 12 hours demonstrated comparable efficacy vs vancomycin plus aztreonam 1 g every 12 hours in terms of clinical cure rates*2
Zinforo was associated with a trend towards early clinical response when compared to vancomycin + aztreonam at Day 33†
Response rate at Day 3
Zinforo delivers high cure rates in patients with severe disease and comorbidities‡2
Clinical response rates at Day 3 (CANVAS 1 and 2 trials)†3
Zinforo was well tolerated with a safety profile consistent with the cephalosporin class.2
Explore More
Read several cSSTI patient profiles describing potential scenarios where Zinforo could be a treatment of choice.
To learn more about the efficacy of Zinforo in a real-world setting, explore the CAPTURE study.
*The lower limit of the 95% CI was above -10%, which met the predefined criteria for non-inferiority.2
‡There is no experience with Zinforo in the treatment of cSSTI in the following patient groups: The immunocompromised; patients with severe sepsis/septic shock; necrotising fasciitis; perirectal abscess; and patients with third-degree and extensive burns. There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.1
†Zinforo was associated with a non-statistical significant early clinical response defined by cessation of lesion spread and absence of fever.3
**Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CE, clinically evaluable; CANVAS, CeftAroliNe fosamil vs VAncomycin in Skin and skin structure infection; CI, confidence interval; MITT, modified intent-to-treat; PORT, Pneumonia Patient Outcomes Research Team; MRSA, Methicillin-resistant Staphylococcus aureus.
Prescribing Information
Zinforo 600 mg powder for concentrate for solution for infusion
- ZINFORO. Summary of Product Characteristics
- Corey G, et al. Clin Infect Dis 2010;51:641-50
- Friedland D, et al. Antimicrob Agents Chemother 2012;56:2231-6
- Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18
- Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
- Drusano, GL. J Antimicrob Chemother 2011;66(Suppl3):iii61–7
Explore the outcomes of the other Zinforo Phase III clinical trials in patients with CAP
Tolerability profile of Zinforo
Access data on the tolerability profile of Zinforo as established in key Phase III clinical trials
** This is an optional area where footnotes can live.
Zinforo has an extended in vitro spectrum of coverage, including key pathogens in CAP and cSSTI**1,4-6
For UK Healthcare Professionals*
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020
No